ArticleDiscover oncology2025
Identification of an efficient immunohistochemical panel for precise differential diagnosis of sebaceous carcinoma of eyelid.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinicopathological characteristics, diagnostic challenges, and systemic implications of metastatic tumors to the eyelid: a systematic review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sebaceous carcinoma (SC) is a prevalent neoplasm of the eyelid, ranking second to basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in incidence. In some Asian regions, the incidence of SC is as high as 50% with a high risk of invasion and recurrence. Diagnosis of SC is still challenging owing to its atypical histological features and variable immunohistochemical profiles, especially in poorly differentiated ones. Therefore, it is critical to identify more precise immunohistochemical makers for the prediction of SC. In this study, we performed a double-blind, retrospective analysis using tissue microarrays to evaluate the diagnostic accuracy of TRPS1, GATA3, and adipophilin in a cohort with 98 SCs, 56 BCCs, and 55 SCCs. Receiver operating characteristic curves analysis and DeLong's test were used to confirm the applicability of these markers. Binary logistic regression was applied to construct a cancer classification model, with model validity confirmed through likelihood ratio tests (Δ-2LL = 255.937, p < 0.001) and pseudo-R² metrics (Cox & Snell R² = 0.706, Nagelkerke R² = 0.803, McFadden R² = 0.578). Variable contributions were assessed via hierarchical likelihood ratio tests and Wald analyses, revealing significant discriminative power of TRPS1 score (OR = 524.410, p < 0.001) and other predictors. Our results revealed that the combination of above three markers significantly enhanced the diagnostic performance compared to individual ones. Notably, TRPS1 and GATA3 demonstrated superior discriminatory power in distinguishing SC from BCC and SCC to adipophilin. In poorly differentiated SCs, TRPS1 exhibited a markedly higher diagnostic efficacy than GATA3 and adipophilin. In addition, TRPS1 exhibited higher AUC values than GATA3 and adipophilin in differentiating primary and recurrent SCs, although the difference was not significant. Collectively, our findings indicate that the TRPS1/GATA3/adipophilin-based model demonstrated excellent discriminatory efficacy for eyelid malignancies (Kappa = 0.784, micro-average F1 = 0.882, AUC-ROC = 0.964 [95%CI:0.934-0.994]), achieving clinical-grade performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.